Trial Profile
A randomized trial to evaluate the efficacy & safety of Pemetrexed and Platinum Vs Gefitinib in Non-Small Cell Lung Cancer patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Pemetrexed
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Oct 2017 Details of Qtwist (quality-adjusted time without symptom or toxicity) analysis method comparing the benefit of gefitinib versus pemetrexed platinum for this trial, presented at the 18th World Conference on Lung Cancer.
- 06 Sep 2016 New trial record